Jump to content

Genomic Health

Edit links
From Wikipedia, the free encyclopedia
Genomic Health, Inc.
Company typeSubsidiary
Nasdaq: GHDX
IndustryGenomics
FoundedAugust 2000; 24 years ago (2000-08), in Redwood City, California, U.S.
FounderRandy Scott
SuccessorExact Sciences
HeadquartersRedwood City, California, U.S.
Key people
ProductsOncotype DX
Number of employees
863 (2017)
Websitewww.genomichealth.com Edit this at Wikidata
Footnotes / references
[1][2][3]

Genomic Health, Inc. is a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California.[2] The company was acquired by and merged with Exact Sciences Corporation in 2019.

History

[edit]

Genomic Health, Inc. was founded in 2000 by Randy Scott, who had previously founded and been CEO at Incyte.[4] He formed the company after a close friend was diagnosed with cancer and had the idea for treatment based on the specific genome of their tumor.[5]

By 2003 Genomic Health had developed Oncotype DX, a genomic assay that quantified the likelihood of breast cancer recurrence.[6] This development took the company over three years and US$30,000,000 to complete and then had to convince skeptics at the time of the validity of genetic testing.[6]

In July 2005 Genomic Health filed for an initial public offering to sell up to US$75,000,000 in common stock. Investors at the time already included Versant Ventures and Kleiner Perkins Caufield & Byers.[7] On September 29, 2005 (2005-09-29) it was listed on the NASDAQ with the symbol GHDX with the initial share price of US$12 for 5016722 shares.[8]

Genomic Health also started a subsidiary in 2010, Invitae, with the goal of aggregating multiple genetics tests. Invitae was spun off in 2012.[9]

The company expanded with international headquarters in Geneva Switzerland and UK headquarters in London in 2011.[10]

In July 2019, Exact Sciences announced that it was purchasing Genomic Health to increase the variety of medical tests they offer.[11]

See also

[edit]

References

[edit]
  1. ^ "US SEC: Form 10-K Genomic Health, Inc". U.S. Securities and Exchange Commission. Retrieved April 3, 2018.
  2. ^ a b "GENOMIC HEALTH, INC". OpenCorporates. 13 December 2016. Retrieved 10 January 2017.
  3. ^ Chaykowsk, Kathleen (10 April 2012). "CEO's dedication is behind Genomic Health's cancer tests". Peninsula Press. Retrieved 10 January 2017.
  4. ^ Susan McKinnon; Sydel Silverman (1 June 2005). Complexities: Beyond Nature and Nurture. University of Chicago Press. p. 239. ISBN 978-0-226-50024-9. Retrieved 10 January 2017.
  5. ^ Cook, Kevin (7 October 2013). "Genomic Health Has Sickly Stock Chart". Forbes. Retrieved 10 January 2017.
  6. ^ a b Chess, Robert; Denend, Lyn; Zenios, Stefanos (2006). "Genomic Health: Launching a Paradigm Shift ... and an Innovative New Test". Stanford Graduate School of Business. Retrieved 10 January 2017.
  7. ^ Simmers, Tim (19 July 2005). "Genomic Health files for an IPO". East Bay Times. Retrieved 10 January 2017.
  8. ^ "GENOMIC HEALTH INC (GHDX) IPO". NASDAQ. Retrieved 10 January 2017.
  9. ^ Lash, Alex (20 October 2015). "What's Your DNA Worth? The Scramble To Cash In On the Genome". exome. Retrieved 10 January 2017.
  10. ^ "Company Timeline & Milestones". Genomic Health. Archived from the original on 30 July 2019. Retrieved 10 January 2017.
  11. ^ Flanagan, Cristin; Ahmed, Nabila (29 July 2019). "Exact Sciences to Buy Genomic Health for About $2.8 Billion". Bloomberg News. Retrieved 30 July 2019.
[edit]
  • Official website Edit this at Wikidata
  • Business data for Genomic Health, Inc.:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Genomic_Health&oldid=1245462887"